Bioceres Crop Solutions Corp. (BIOX) stock analysis

BIOXNasdaqAgricultural ChemicalsFiscal year ends June 30

Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Oct 30, 2026Score 1/30

$0.23+0.02 (+8.48%)

Close on Nov 11, 2026Market cap $14.85MP/E –Yield –

StockData Score

Prices as of Nov 11, 2026How the score works

Weak1 of 30 checks passed

Bioceres Crop Solutions passes 1 of the 30 checks behind our score; 20 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation: 0/6
Growth: 0/6
Past performance: 0/6
Financial health: 1/6
Dividend: 0/6

What stands out

Debt covered by cash flow
Operating cash flow over the last twelve months equals 61.6% of total debt.

What to watch

Return on capital under 10%
Return on invested capital was -7.4%, below the 10% that usually covers the cost of capital.
High debt
Debt is 1001% of shareholders' equity, above the 40% we consider low.
Revenue growing under 10% a year
Revenue grew -17.2% a year over the last three fiscal years, short of the 10% we look for.
Interest not well covered
Operating income covers interest expense -0.6 times; we look for at least 5.

Valuation0/6

P/E against its history
Not enough price and earnings history to compare.
P/E against the industry
Needs positive earnings and enough profitable companies in the industry.
EV/EBITDA against its history
Needs positive EBITDA and price history.
P/B against the industry
Needs positive book value.
Price against fair value
We could not estimate a fair value: it needs at least two valuation methods with positive inputs.
Margin of safety
Depends on the fair value estimate.

Growth0/6

Revenue growing under 10% a year
Revenue grew -17.2% a year over the last three fiscal years, short of the 10% we look for.
EPS growth over 3 years
Needs positive EPS three years ago and today.
Earnings acceleration
Needs positive net income now, a year ago and five years ago.
Growing slower than the industry
Revenue grew -17.7% over the last twelve months; the Chemicals and Allied Products median is 3.5%.
Company guidance
No outlook found in earnings releases from the last twelve months.
Gross margin slipping
Gross margin was 34.9% over the last twelve months, against 36.3% a year earlier.

Past performance0/6

Return on equity
Needs positive equity and five years of results.
Return on capital under 10%
Return on invested capital was -7.4%, below the 10% that usually covers the cost of capital.
Return on equity against the industry
Needs positive equity.
Earnings over 5 years
Needs positive net income five years ago and in the latest year.
Net margin against its history
Needs five years of revenue and net income.
Net margin against the industry
Needs revenue and net income.

Financial health1/6

High debt
Debt is 1001% of shareholders' equity, above the 40% we consider low.
Debt rising against equity
Debt to equity rose from 184% five years ago to 1001%.
Debt covered by cash flow
Operating cash flow over the last twelve months equals 61.6% of total debt.
Interest not well covered
Operating income covers interest expense -0.6 times; we look for at least 5.
Short-term assets don't cover short-term debts
Current assets are 0.80 times current liabilities.
Bankruptcy risk (Altman Z)
Needs market value, working capital and retained earnings.

Dividend0/6

No dividend
Bioceres Crop Solutions has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.

Scores of similar companies

Fair value

How we estimate it

We don't publish a fair value for Bioceres Crop Solutions. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

High risk

Average value traded per day: $52.66K
Value traded per 1% price move: $10.66K

Downside

High risk

Typical loss in a bad month: 56.0%
Volatility (annualized): 99%
Sharpe ratio, 1 year: -0.91
Beta to the S&P 500 (5Y): 0.76

Typical bad-month loss, week by week

Margins

Share of revenue, fiscal years 2016 to 2026

Gross margin

34.9%−8.5 pts over 5 years

Operating margin

-9.8%−28.1 pts over 5 years

Net margin

–

Per year	1 year	3 years	5 years	10 years
Revenue	-17.7%	-17.2%	+2.6%	+19.2%
Gross profit	-20.8%	-23.3%	-1.8%	+22.9%
Free cash flow	+45.2%	–	–	–

Returns and balance sheet

9 fiscal years. Hover a measure to see how it is calculated.

Measure	FY2016	FY2021	FY2026
Return on equity	–	-12.1%	–
Return on assets	–	-2.0%	–
Current ratio	–	1.26	0.80
Debt to equity	–	1.84	10.01
Interest coverage	0.0×	1.8×	-0.6×
Inventory turnover	–	2.6×	2.3×
Capex to revenue	1.5%	1.3%	0.4%
Diluted shares	28M	39M	64M

DuPont analysis

Return on equity split into margin, efficiency and leverage

Net margin-19.1%

Asset turnover0.36×

Equity multiplier2.78×

Return on equity, FY2025-19.1%

Fiscal year	Net margin	Asset turnover	Equity multiplier	Return on equity
FY2025	-19.1%	0.36×	2.78×	-19.1%
FY2024	1.0%	0.50×	2.72×	1.4%
FY2023	4.5%	0.63×	3.14×	8.8%
FY2022	-2.2%	0.73×	4.68×	-7.4%
FY2021	-3.3%	0.61×	6.08×	-12.1%
FY2020	1.9%	0.64×	5.78×	7.2%

Where these numbers come from

Parsed from the XBRL in Bioceres Crop Solutions's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing